- About
-
Projects
-
Column 1
- Advancing Regulatory Science
- Animal Health & Veterinary Medicine
- Expanded Access
- FDA Patient Listening Sessions
-
Column 2
- Food & Nutrition
- Improving Access to FDA Information
- Research
- Substance Use Disorders
-
Column 1
- News and Events
- Expanded Access eRequest
Coverage
Researchers from the University of California San Diego have found that U.S. overdose death rates declined dramatically between 2023 and 2024, marking the first recorded drop in all four waves of the nation’s overdose crisis.
At the Vitalist Bay longevity conference, dreamers and entrepreneurs launch an industry.
Endpoints News Executive Editor Drew Armstrong leads a conversation on China biopharma at the Financial Times summit, with Susan Winckler, CEO of the Reagan-Udall Foundation for the FDA, and Caitlin Frazer, executive director of the National Security…
Co-sponsored by XPRIZE Healthspan and ARPA-H's PROSPR program, this public meeting — convened by the Reagan-Udall Foundation for the FDA — will bring together FDA leadership, select awardees, academic researchers, product developers, clinicians, and…
The U.S. biotech industry is facing a major global rival for the first time. In response to the Chinese life science industry’s rapid growth, U.S. policymakers and regulators are racing to support Western innovation while maintaining patient safety.
Oncology clinical trials represent a dynamic frontier where site selection optimization directly influences the pace of innovation and the relevance of therapeutic advances.
In September 2024, a stakeholder roundtable report published by the Reagan-Udall Foundation for the FDA indicated that industry stakeholders may not be aware of or prepared to be in compliance with the rule by January 2026.
Moderator Michael McCaughan and Dr. Amy Abernethy kicked off the fireside chat by reflecting on the evolution of RWD, including prior efforts such as the Friends RWD Pilot 1.0 Project and the COVID-19 Evidence Accelerator led by Friends and the Reagan-…
The FDA Public Engagement Staff, along with the Reagan-Udall Foundation, hosted the virtual event that was moderated by Aviva Strategies. The listening session provided a direct connection between the agency and the PF community allowing for better…
A new report from the Reagan-Udall Foundation for the Food and Drug Administration (FDA) has distilled longstanding challenges in rare disease drug development into 20 specific recommendations, aiming to consolidate years of regulatory dialogue into an…